Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Science advances - 22 Jul 2022

Mugarza Edurne, van Maldegem Febe, Boumelha Jesse, Moore Christopher, Rana Sareena, Llorian Sopena Miriam, East Philip, Ambler Rachel, Anastasiou Panayiotis, Romero-Clavijo Pablo, Valand Karishma, Cole Megan, Molina-Arcas Miriam, Downward Julian

Abstract excerpt

Recently developed KRASG12C inhibitory drugs are beneficial to lung cancer patients harboring KRASG12C mutations, but drug resistance frequently develops. Because of the immunosuppressive nature of the signaling network controlled by oncogenic KRAS, these drugs can indirectly affect antitumor immunity, providing a rationale for their combination with immune checkpoint blockade. In this study, we have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Checkpoint Inhibitors
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35857848
DOI: 10.1126/sciadv.abm8780
PMCID: PMC9299537

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.PMID 35857848Read ↗

Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancersSemantic proximity Read ↗

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.Semantic proximity Read ↗

KRAS G12C inhibition and innate immune targeting.Semantic proximity Read ↗

Low STING expression in a transplantable Kras <sup>G12D</sup> /P53 <sup>ko</sup> lung cancer model contributes to SiglecF <sup>+</sup> neutrophil and CD103 <sup>+</sup> Treg accumulation in tumorsSemantic proximity Read ↗

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.Semantic proximity Read ↗

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.Semantic proximity Read ↗

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.Semantic proximity Read ↗

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.Semantic proximity Read ↗

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung AdenocarcinomaSemantic proximity Read ↗

Evaluation of KRAS <sup>G12C</sup> Inhibitor Responses in Novel Murine KRAS <sup>G12C</sup> Lung Cancer Cell Line ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.